Anti-SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021

JAMA. 2022 Mar 8;327(10):980-983. doi: 10.1001/jama.2022.1243.

Abstract

This study assesses how a limited supply of monoclonal antibody therapy was allocated to patients at highest risk of severe disease among a population of fee-for-service Medicare beneficiaries with a new COVID-19 diagnosis or confirmed exposure between November 2020 and August 2021.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • COVID-19 / drug therapy*
  • Humans
  • Medicare
  • Prescription Drugs / supply & distribution
  • Risk Assessment
  • United States

Substances

  • Antibodies, Monoclonal
  • Prescription Drugs

Supplementary concepts

  • COVID-19 drug treatment